Výsledky vyhledávání - "Lois Brafman"

Randomized controlled trial of a clinic-based survivorship intervention following adjuvant therapy in breast cancer survivors

Autor: Grace Kranwinkel, Ramona Jayasena, Heather Greenlee, Wei-Yann Tsai, Danielle Awad, Dawn L. Hershman, Katherine D. Crew, Lois Brafman, Kevin Kalinsky, Alfred I. Neugut, Matthew Maurer

Publikováno v: Breast Cancer Research and Treatment. 138:795-806

In 2006, the IOM released a report citing the importance of "survivorship plans" to improve quality of life and care coordination for cancer survivors, but little has been done to evaluate their efficacy. Women with early-stage breast cancer were ran

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::748c06ef0f752f64157b5dea485cdf16
https://doi.org/10.1007/s10549-013-2486-1

Zobrazit plný text záznamu

Survivorship care plans and adherence to lifestyle recommendations among breast cancer survivors

Autor: Dawn L. Hershman, Kevin Kalinsky, Katherine D. Crew, Lois Brafman, Wei-Yann Tsai, Christine L. Sardo Molmenti, Heather Greenlee, Danielle Awad, Alfred I. Neugut, D. Fuentes, Zaixing Shi

Publikováno v: Journal of cancer survivorship : research and practice. 10(6)

The effectiveness of survivorship care plans has not been widely tested. We evaluated whether a one-time brief lifestyle consultation as part of a broader survivorship care plan was effective at changing diet and lifestyle patterns.A diverse sample o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::111a69323d3643c5e9bd193386f68570
https://pubmed.ncbi.nlm.nih.gov/27100859

Zobrazit plný text záznamu

Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer

Autor: Theresa Shao, Katherine D. Crew, Lois Brafman, Grace Kranwinkel, Heather Greenlee, Dawn L. Hershman, Kevin Kalinsky, Beverly J. Insel, Matthew Maurer, Wei-Yann Tsai

Publikováno v: Supportive Care in Cancer. 21:1077-1087

Many women with hormone receptor-positive breast cancer discontinue effective aromatase inhibitor (AI) treatment due to joint symptoms.We conducted a single-arm, open-label, phase II study evaluating glucosamine-sulfate (1,500 mg/day) + chondroitin-s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38415760718af845bc72bdd1fb647453
https://doi.org/10.1007/s00520-012-1628-z

Zobrazit plný text záznamu

Abstract P1-07-01: Safety of High-Dose Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer

Autor: Matthew A. Maurer, Lois Brafman, Sheldon Feldman, Kd. Crew, Dawn L. Hershman, Kevin Kalinsky, Susan Refice

Publikováno v: Cancer Research. 70:P1-07

Background: Vitamin D has diverse biological effects on proliferation, differentiation, and apoptosis in multiple tissues, including the breast. Observational studies have demonstrated that serum 25-hydroxyvitamin D (25-OHD), an objective measure of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::09ebf058044e85565df63ea272a2aa45
https://doi.org/10.1158/0008-5472.sabcs10-p1-07-01

Zobrazit plný text záznamu

Prevention of Bone Loss by Zoledronic Acid in Premenopausal Women Undergoing Adjuvant Chemotherapy Persist up to One Year following Discontinuing Treatment

Autor: Danielle Awad, Dawn L. Hershman, Theresa Shao, Elizabeth Shane, Lois Brafman, Donald J. McMahon, Katherine D. Crew, Serge Cremers

Publikováno v: The Journal of Clinical Endocrinology & Metabolism. 95:559-566

Context: Adjuvant chemotherapy is associated with significant reductions in bone mineral density (BMD) in premenopausal women with breast cancer (BC) that is prevented with zoledronic acid (ZA) every 3 months for 1 yr. Objective: The aim of the study

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b92a8440fe5ed8f28de4849032cc50b7
https://doi.org/10.1210/jc.2009-1366

Zobrazit plný text záznamu

Zoledronic Acid Prevents Bone Loss in Premenopausal Women Undergoing Adjuvant Chemotherapy for Early-Stage Breast Cancer

Autor: Lois Brafman, Elizabeth Shane, Katherine D. Crew, Gina Cucchiara, Donald J. McMahon, Serge Cremers, Dawn L. Hershman, Dinaz Irani

Publikováno v: Journal of Clinical Oncology. 26:4739-4745

Purpose Adjuvant chemotherapy for breast cancer (BC) may be associated with increased rates of bone loss and decreased bone mineral density (BMD) and may lead to premature osteoporosis and increased fracture risk. We examined whether zoledronic acid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a83140aacae0ae92d53c99cb49c50e01
https://doi.org/10.1200/jco.2008.16.4707

Zobrazit plný text záznamu

Prevalence of Joint Symptoms in Postmenopausal Women Taking Aromatase Inhibitors for Early-Stage Breast Cancer

Autor: Katherine D. Crew, Lois Brafman, Alex Sierra, D. Fuentes, George Raptis, Dawn L. Hershman, Heather Greenlee, Jillian L. Capodice

Publikováno v: Journal of Clinical Oncology. 25:3877-3883

Purpose Aromatase inhibitors (AIs) improve survival in postmenopausal women with hormone-sensitive breast cancer, but can cause joint pain and stiffness. The purpose of the current study was to evaluate the prevalence of and identify risk factors for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba46d6ba09a1773d78e5eef69042cd30
https://doi.org/10.1200/jco.2007.10.7573

Zobrazit plný text záznamu

Safety, Feasibility, and Biomarker Effects of High-Dose Vitamin D Supplementation Among Women at High Risk for Breast Cancer

Autor: Katherine D. Crew, Mathew S. Maurer, Dawn L. Hershman, Lois Brafman, Tong Xiao, Refice, Thomas Ps, Sheldon Feldman, Kevin Kalinsky, Mary Beth Terry

Publikováno v: International journal of food science, nutrition and dietetics

Vitamin D deficiency is a potentially modifiable risk factor that may be targeted for breast cancer prevention. We examinedthe safety, feasibility, and biomarker effects of high-dose vitamin D among women at high risk for breast cancer. Forty high-ri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a30b829dc2b19f363a2446d186cfdbf
https://zenodo.org/record/47688

Zobrazit plný text záznamu

A Phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma

Autor: Linda T. Vahdat, Daniel P. Petrylak, Caron Nelsen, Andrea Troxel, Karen H. Antman, Susan Talbot, Laureen Shriberg, Robert L. Fine, Amy Tiersten, Lois Brafman

Publikováno v: Cancer. 97:537-544

BACKGROUND The similarity between the mechanism of action between docetaxel and estramustine generated the hypothesis of synergistic antimicrotubule effects and cytotoxicity when the two agents are combined. In addition, it has been demonstrated that

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::942783e23ed53e2929f255e0f64156d2
https://doi.org/10.1002/cncr.11082

Zobrazit plný text záznamu

Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy

Autor: Louis H. Weimer, Lois Brafman, Grace Kranwinkel, Antai Wang, Katherine D. Crew, Dawn L. Hershman, Danielle Awad, D. Fuentes

Publikováno v: Breast cancer research and treatment. 125(3)

Neurotoxicity is a common side-effect during taxane therapy. The prevalence and severity of long-term neurotoxicity following therapy is unknown. The authors conducted a cross-sectional study of 50 consecutive patients with stage I–III BC, who were

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::601be9297676590e209a3e815f2cdb6b
https://pubmed.ncbi.nlm.nih.gov/21128110

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání